1. Home
  2. CODA vs ICCC Comparison

CODA vs ICCC Comparison

Compare CODA & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Coda Octopus Group Inc.

CODA

Coda Octopus Group Inc.

HOLD

Current Price

$10.08

Market Cap

113.3M

Sector

Industrials

ML Signal

HOLD

Logo ImmuCell Corporation

ICCC

ImmuCell Corporation

HOLD

Current Price

$9.92

Market Cap

93.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CODA
ICCC
Founded
1994
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
113.3M
93.1M
IPO Year
2007
1995

Fundamental Metrics

Financial Performance
Metric
CODA
ICCC
Price
$10.08
$9.92
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
58.3K
27.2K
Earning Date
06-15-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
15.62
53.85
EPS
0.23
0.41
Revenue
$20,316,161.00
$26,493,169.00
Revenue This Year
$18.28
N/A
Revenue Next Year
$12.62
N/A
P/E Ratio
$43.70
$23.88
Revenue Growth
4.98
51.64
52 Week Low
$7.80
$4.52
52 Week High
$18.00
$12.10

Technical Indicators

Market Signals
Indicator
CODA
ICCC
Relative Strength Index (RSI) 49.52 39.51
Support Level $9.85 $9.36
Resistance Level $10.50 $10.75
Average True Range (ATR) 0.32 0.41
MACD -0.01 -0.04
Stochastic Oscillator 33.02 18.55

Price Performance

Historical Comparison
CODA
ICCC

About CODA Coda Octopus Group Inc.

Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company operates in three distinct business segments: the Marine Technology business, Acoustic Sensors and Material Business and the Defense Engineering Services Business. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.

About ICCC ImmuCell Corporation

ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.

Share on Social Networks: